# Pharmacokinetic, Safety, Tolerability, and Clinical Effect of Topical Umeclidinium in Primary Axillary Hyperhidrosis

> **NCT02563899** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 28 (actual)

## Conditions studied

- Hyperhidrosis

## Interventions

- **DRUG:** Umeclidinium
- **DRUG:** Vehicle

## Key facts

- **NCT ID:** NCT02563899
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11-23
- **Primary completion:** 2016-02-25
- **Final completion:** 2016-02-25
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2018-10-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02563899

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02563899, "Pharmacokinetic, Safety, Tolerability, and Clinical Effect of Topical Umeclidinium in Primary Axillary Hyperhidrosis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02563899. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*